Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microsco

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes, for freely moving animal brain imaging. Since its founding in 2011, Inscopix's flagship miniscope systems have been deployed in over 600 research institutions and biopharma companies worldwide, empowering breakthroughs in fundamental neuroscience research and advancing the understanding of mechanisms in neurological disorders. This acquisition enhances Bruker’s strong reputation as a technology leader for in-vivo brain functional imaging with Ultima multiphoton microscopes at the cellular level and preclinical MRI systems at the organismal level. “We are very proud of how far Inscopix has come in 10 years,” said Dr. Kunal Ghosh, Founder and CEO of Inscopix. “We’ve built an end-to-end ecosystem for neuroscience research, from reagents and streamlined workflow solutions to a full analysis pipeline. This acquisition will accelerate our mission of enabling a better understanding of the neural circuitry underpinning brain function and behavior, and to assist the development of new and better neurotherapeutics by our biopharma partners. As part of Bruker, we can take the next step in technology and new platform development for both academic and pharma customers.”

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding the market availability for its Inscopix Data Exploration, Analysis and Sharing (IDEAS) Platform to include individual labs, which allows academic researchers to vastly improve how they share, analyze and organize neuroscience data. Initially launched in December 2021 as enterprise-friendly solution and then showcased at FENS Forum 2022 with the workflow for analyzing neural circuit modulation, the cloud-based IDEAS Platform is the first-of-its-kind turnkey solution for processing multimodal preclinical research data with its powerful, intuitive database solution and scalable compute infrastructure. Addressing one of the major roadblocks in current brain research efforts, IDEAS supports the organization, multi-modal integration, analysis and sharing of neuroscience imaging data and methods to accelerate basic research and catalyze progress towards the next-generation of neurotherapeutics